Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors

US6670357B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Katerina Leftheris · Skillman, US
• John Hynes · Washington Crossing, US
• Stephen T. Wrobleski · Whitehouse Station, US
• Joel C. Barrish · Richboro, US

Key dates

• Filing date: Nov 7, 2001
• Grant date: Dec 30, 2003
• Expiry date: Dec 4, 2021

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D207/50
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Methods of treating one or more conditions associated with p38 kinase activity are disclosed comprising administering to a patient in need thereof at least one compound having the formula (I): or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein R3 is hydrogen, methyl, perfluoromethyl, methoxy, halogen, cyano, or NH2, preferably methyl, and X, R1 through R6, and Z are as described in the specification. Advantageously the groups —ZR4R5 taken together comprise an —NH-substituted aryl.